Get the Stockscreener App
10.14
1.46%
-0.15
Adaptive Biotechnologies Corp stock is traded at $10.14, with a volume of 1.19M.
It is down -1.46% in the last 24 hours and up +12.04% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$10.29
Open:
$10.25
24h Volume:
1.19M
Relative Volume:
0.57
Market Cap:
$1.59B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-7.5672
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-3.06%
1M Performance:
+12.04%
6M Performance:
+55.52%
1Y Performance:
+222.93%
1-Day Range:
$10.11
$10.44
1-Week Range:
$9.90
$10.87
52-Week Range:
$2.99
$10.87
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
10.14 | 1.59B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies reports annual meeting outcomes By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies reports annual meeting outcomes - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by California State Teachers Retirement System - Defense World
Adaptive Biotechnologies at Goldman Sachs Conference: Strong Q1 Performance and Strategic Growth - Investing.com
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
118,593 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Raises Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Nasdaq Today Adaptive Biotechnologies’ Role in Innovation Kalkine - Kalkine Media
ADPT stock soars to 52-week high, hits $10.28 amid surge - Investing.com India
Two Sigma Advisers LP Has $309,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Two Sigma Investments LP Has $1.10 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Bank of America Corp DE - Defense World
Cathie Wood’s ARK buys Guardant Health, sells Adaptive Biotechnologies stock - Investing.com Nigeria
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at Key Conferences | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - The Manila Times
Adaptive Biotechnologies’ MRD test featured in cancer studies - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
BNP Paribas Financial Markets Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock - Investing.com
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Ameriprise Financial Inc. Has $4.42 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Janus Henderson Group PLC Buys Shares of 46,900 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Catherine Wood Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus
Northern Trust Corp Acquires 130,449 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Jane Street Group LLC Sells 97,690 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Lowered by Price T Rowe Associates Inc. MD - Defense World
Does Adaptive Biotechnologies Corp (NASDAQ: ADPT) Still Look Hot This Week? - Stocksregister
16,457 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by First Trust Advisors LP - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? - Yahoo Finance
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
FDA posts regulation for 2018 test for hematological malignancies - BioWorld MedTech
Brokerages Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Price Target at $9.50 - Defense World
Trading Day Review: Adaptive Biotechnologies Corp (ADPT) Loses Momentum, Closing at 8.81 - DWinneX
MetLife Investment Management LLC Acquires 3,650 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (ADPT) Price Target Raised by Piper San - GuruFocus
Adaptive Biotechnologies (ADPT) Price Target Raised by Piper Sandler | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Reaches Analyst Target Price - Nasdaq
ADPT Price Target Increased to $13 by Piper Sandler | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $9.00 at Morgan Stanley - Defense World
Adaptive Biotechnologies (ADPT) Price Target Raised by Morgan St - GuruFocus
5 Analysts Assess Adaptive Biotechnologies: What You Need To Know - Benzinga
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Stock Forecast: Downside Of -42.28% By 2025 - Stocksregister
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):